Cochrane · systematic review · CD012713
Ribavirin for treating Crimean Congo haemorrhagic fever
Johnson, S, Henschke, N, Maayan, N, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 4 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Ribavirin versus no ribavirin for Crimean Congo haemorrhagic fever
Population: people diagnosed with suspected or confirmed Crimean Congo haemorrhagic fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality Ribavirin vs no ribavirin | RR 1.13 [0.29, 4.32] | 1 study · 136 participants | Very low Downgraded: risk of bias, imprecision |
Length of hospital stay (days) Ribavirin vs no ribavirin | no estimate extracted | 1 study · 136 participants | Very low Downgraded: risk of bias, imprecision |
Requirement for transfusion (platelets) Ribavirin vs no ribavirin | RR 1.23 [0.77, 1.96] | 1 study · 136 participants | Very low Downgraded: risk of bias, imprecision |
Early versus late supportive care plus ribavirin for Crimean Congo haemorrhagic fever
Population: people diagnosed with suspected or confirmed Crimean Congo haemorrhagic fever
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mortality in early versus late supportive care plus ribavirin Early vs late supportive care plus ribavirin | RR 0.39 [0.16, 0.95] | 63 participants | Very low Downgraded: risk of bias, imprecision |